Ara
Toplam kayıt 2, listelenen: 1-2
68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case report
(Sage Publications Ltd, 2020)
Introduction Lung cancer still ranks first among the most common and most lethal cancers today. The most common subtype is non-small cell lung cancer, and in this group, adenocarcinoma has the worst prognosis. EGFR, ROS1 ...
Which tyrosine kinase inhibitor must we apply before? A case report of crizotinib-resistant patient with concomitant EGFR and EML4-ALK gene mutations
(University of the West Indies, 2021)
The concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocations in lung adenocancers are very rare scenarios. Until now, 42 cases described in the literature have all ...